Targovax is a clinical stage immuno-oncology company developing immune activators for combination therapy in cancer. Targovax has a diversified immune activator portfolio and aims to become a leader in this area. The Company’s lead product, ONCOS-102, is an oncolytic adenovirus armed with an immune-stimulating transgene, which is currently being investigated in four ongoing clinical trials.
IR Contact
News
-
September 18, 2020Targovax ASA: Registration of share capital increase following settlement of restricted stock units
-
September 14, 2020Targovax is invited to present at H.C. Wainwright 22[nd] Annual Global Investment Conference
-
September 2, 2020Targovax is invited to present at Pareto Nordic Healthcare conference and RAS-targeted drug development summit
-
August 31, 2020Targovax ASA: Settlement of restricted stock units by primary insider and resolution to increase the share capital
Second quarter 2020
Targovax ASA (OSE: TRVX) announced its second quarter 2020 results on Thursday 20 August 2020.